|Table of Contents|
Surgical treatment of non-small-cell lung cancer
The current treatment of lung cancer is characterized by a broader interpretation of the term ‘targeted therapy’, which actually refers to the selective manipulation of molecular targets by neoadjuvant and/or adjuvant chemotherapy. The concept of targeted therapy may, however, also be translated to thoracic surgery in the sense that – despite greatly reduced invasiveness – treatment options with increased effectiveness and selectivity can be offered.In this paper, the current surgical treatment of all stages of non-small-cell lung cancer will be reviewed. The presented literature will show that – thanks to constantly renewing technology – radical and oncologically correct surgical treatment of bronchial carcinoma of the highest quality is possible for almost all stages. Thus, even locally advanced tumours can no longer be considered as an obstacle to cure. On the other hand – in tune with the overall trend of reduced invasiveness and enhanced effectiveness – sublobar resection for T1a tumours is gaining increasing acceptance amongst thoracic surgeons worldwide. The oncological radicality of limited lung resection can be further increased by innovative minimally invasive approaches to mediastinal lymphadenectomy. In conclusion, the paramount importance of radical mediastinal lymphadenectomy for patients’ survival is emphasized once more by the current literature.